# Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer

Source: https://onco.cc/trials/nct07827053/  
OnCo record `nct07827053` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of adebrelimab and nALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV) in pancreatic cancer, run by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, not yet recruiting.

## Summary

Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer is a phase 2, interventional study registered as NCT07827053 by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, with a registry enrolment figure of 36 participants, started 2026-09-01 and due to reach its primary completion in 2029-09-01. Interventions recorded: Adebrelimab (PD-L1 inhibitor); NALIRIFOX; SBRT. Conditions listed: Pancreatic Ductal Adenocarcinoma (PDAC). Primary outcome: surgical conversion rate. Pancreatic eligibility wording from the registry: "Histologically or cytologically confirmed pancreatic ductal adenocarcinoma". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; pancreatic-deep-dive
- Registry id: NCT07827053
- Phase: 2
- Setting: Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
- Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- Enrolled: 36

## Sources

- ClinicalTrials.gov NCT07827053: https://clinicaltrials.gov/study/NCT07827053

## Connected records

- cancers: [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Platinum agents](https://onco.cc/technologies/platinum/), [SBRT / SABR (stereotactic radiotherapy)](https://onco.cc/technologies/sbrt/), [Topoisomerase-I inhibitors (and ADC payloads)](https://onco.cc/technologies/topoisomerase-inhibitors/)
- drugs: [Adebrelimab](https://onco.cc/drugs/adebrelimab/), [NALIRIFOX (liposomal irinotecan + oxaliplatin + 5-FU/LV)](https://onco.cc/drugs/nalirifox/)
- terms: [Pancreatic cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/pancreatic-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07827053.json